ArticleCancer immunology, immunotherapy : CII2018

Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice.

Jill P Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.